A clinical trial to compare the combination of Lornoxicam and Paracetamol with Lornoxicam alone in relieving pain and other symptoms.

A comparative clinical trial for the evaluation of the efficacy and safety of FDC of Lornoxicam (4 mg) and Paracetamol (500 mg)with Lornoxicam (4 mg) alone for short term treatment of mild to moderate pain associated with extra articular inflammation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2009/091/000056

Enrollment

201

Registered

2010-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Lornoxicam, Paracetamol: FDC Control Intervention1: Lornoxicam: 4 mg

Eligibility

Inclusion criteria

Inclusion criteria: Patients with either sex, from 18-60 years age. Informed consent, extra articular inflammation.

Exclusion criteria

Exclusion criteria: Female pregnant or with chances of pregnancy or nursing, History of allergy or hypersensitivity. physical/clinical abnormalities, any condition which affect study of drug.

Design outcomes

Primary

Measure	Time frame
Efficacy and safety of combinationTimepoint: 5 days	—

Secondary

Measure	Time frame
Tolerability and safety of the productTimepoint:	—

Countries

India

Contacts

Public ContactDr. Manish Maladkar

scientific@aristopharma.org02226739999

Outcome results